Together, these data are consistent with DTM regulation of dystrophin protein levels during disease and support therapeutic induction of dystrophin protein as a novel therapeutic mechanism for vamorolone in BMD and as a DMD exon-skipping co-therapy. This evidence concerns the gene DMD and Becker muscular dystrophy.